Mechanisms of prion-induced neurodegeneration

Expert Reviews in Molecular Medicine

Volumn 18, Issue , 2016, Pages

  Saá, Paula ^b   Harris, David A ^a   Cervenakova, Larisa ^b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HOLLAND LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS REGULATORY PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE; PRION; TRANSCRIPTION FACTOR; UBIQUITIN;

ANIMAL; APOPTOSIS; AUTOPHAGY; CENTRAL NERVOUS SYSTEM; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; NERVE CELL; PATHOGENICITY; PATHOLOGY; PRION; PRION DISEASES; PROTEIN FOLDING; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; AUTOPHAGY; CENTRAL NERVOUS SYSTEM; GENE EXPRESSION REGULATION; HUMANS; NAD; NEURONS; PRION DISEASES; PRIONS; PROTEIN FOLDING; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; UBIQUITIN;

EID: 84964000628     PISSN: 14623994     EISSN: None     Source Type: Journal    
DOI: 10.1017/erm.2016.8     Document Type: Review

References (248)

1. Prusiner S.B. (1982) Novel proteinaceous infectious particles cause scrapie. Science 216, 136-144
2. Prusiner S.B. (2012) Cell biology. A unifying role for prions in neurodegenerative diseases. Science 336, 1511-1513
3. Puoti G. et al. (2012) Sporadic human prion diseases: molecular insights and diagnosis. Lancet Neurology 11, 618-628
4. Moody K.M. et al. (2011) Sporadic fatal insomnia in a young woman: a diagnostic challenge: case report. BMC Neurology 11, 136
5. Notari S. et al. (2014) Transmission characteristics of variably protease-sensitive prionopathy. Emerging Infectious Diseases 20, 2006-2014
6. Diack A.B. et al. (2014) Variably protease-sensitive prionopathy, a unique prion variant with inefficient transmission properties. Emerging Infectious Diseases 20, 1969-1979
7. Gambetti P. et al. (2008) A novel human disease with abnormal prion protein sensitive to protease. Annals of Neurology 63, 697-708
8. Liberski P.P. and Budka H. (2004) Gerstmann-Straussler-Scheinker disease. I. Human diseases. Folia Neuropathologica 42 (Suppl B), 120-140
9. Brown P. (1994) Transmissible human spongiform encephalopathy (Infectious cerebral amyloidosis): Creutzfeldt-Jakob Disease, Gerstmann-Sträussler-Scheinker Syndrome and Kuru. In Neurodegenerative Diseases (Calne D.B. ed.), p. 38. W.B.Saunders, Philadelphia
10. Gambetti P. et al. (1999) Inherited prion diseases. In Prion Biology and Diseases (Monograf 38 edn) (Prusiner S. ed.), p. 74. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York
11. Mastrianni J.A. (1993) Genetic prion diseases. In GeneReviews(R) (Pagon R.A., Adam M.P., Ardinger H.H., Wallace S.E., Amemiya A., Bean L.J.H., Bird T.D., Fong C.T., Mefford H.C., Smith R.J.H. and Stephens K. eds), pp. 1993-2016. University of Washington, Seattle, WA
12. Will R.G. et al. (1996) A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 347, 921-925
13. Brown P. et al. (2012) Iatrogenic Creutzfeldt-Jakob disease, final assessment. Emerging Infectious Diseases 18, 901-907
14. Liberski P.P. et al. (2012) Kuru: genes, cannibals and neuropathology. Journal of Neuropathology and Experimental Neurology 71, 92-103
15. Collinge J. et al. (2006) Kuru in the 21st century – an acquired human prion disease with very long incubation periods. Lancet 367, 2068-2074
16. Gajdusek D.C. (1977) Unconventional viruses and the origin and disappearance of kuru. Science 197, 943-960
17. Alpers M.P. (1987) Epidemiology and clinical aspects of Kuru. In Prions (Prusiner S.B. and McKinley M.P. eds), p. 451-465. Academic Press, San Diego
18. Tange R.A., Troost D. and Limburg M. (1990) Progressive fatal dementia (Creutzfeldt-Jakob disease) in a patient who received homograft tissue for tympanic membrane closure. European Archives of Oto-rhino-laryngology 247, 199-201
19. Llewelyn C.A. et al. (2004) Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 363, 417-421
20. Gillies M. et al. (2009) A retrospective case note review of deceased recipients of vCJD-implicated blood transfusions. Vox Sanguinis 97, 211-218
21. Peden A.H. et al. (2004) Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 364, 527-529
22. Wroe S.J. et al. (2006) Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: a case report. Lancet 368, 2061-2067
23. Montagna P. et al. (2003) Familial and sporadic fatal insomnia. Lancet Neurology 2, 167-176
24. Hunter N. (1997) PrP genetics in sheep and the applications for scrapie and BSE. Trends in Microbiology 5, 331-334
25. Mead S. (2006) Prion disease genetics. European Journal of Human Genetics 14, 273-281
26. Kovacs G.G. and Budka H. (2009) Molecular pathology of human prion diseases. International Journal of Molecular Sciences 10, 976-999
27. Collinge J., Palmer M.S. and Dryden A.J. (1991) Genetic predisposition to iatrogenic Creutzfeldt-Jakob disease. Lancet 337, 1441-1442
28. Palmer M.S. et al. (1991) Homozygous prion protein genotype predisposes to sporadic Creutzfeldt-Jakob disease. Nature 352, 340-342
29. Palmer M.S. and Collinge J. (1993) Mutations and polymorphisms in the prion protein gene. Human Mutation 2, 168-173
30. Belt P.B. et al. (1995) Identification of five allelic variants of the sheep PrP gene and their association with natural scrapie. Journal of General Virology 76 (Pt 3), 509-517
31. Lee H.S. et al. (2001) Increased susceptibility to Kuru of carriers of the PRNP 129 methionine/methionine genotype. Journal of Infectious Diseases 183, 192-196
32. Gambetti P. et al. (2011) Molecular biology and pathology of prion strains in sporadic human prion diseases. Acta Neuropathologica 121, 79-90
33. Hill A.F. et al. (2003) Molecular classification of sporadic Creutzfeldt-Jakob disease. Brain 126 (Pt 6), 1333-1346
34. Collinge J. and Clarke A.R. (2007) A general model of prion strains and their pathogenicity. Science 318, 930-936
35. Sabuncu E. et al. (2003) PrP polymorphisms tightly control sheep prion replication in cultured cells. Journal of Virology 77, 2696-2700
36. Rigter A. and Bossers A. (2005) Sheep scrapie susceptibility-linked polymorphisms do not modulate the initial binding of cellular to disease-associated prion protein prior to conversion. Journal of General Virology 86 (Pt 9), 2627-2634
37. Thackray A.M. et al. (2011) Emergence of multiple prion strains from single isolates of ovine scrapie. Journal of General Virology 92 (Pt 6), 1482-1491
38. Hill A.F. et al. (1997) The same prion strain causes vCJD and BSE. Nature 389, 448-450, 526
39. Collinge J. (2001) Prion diseases of humans and animals: their causes and molecular basis. Annual Review of Neuroscience 24, 519-550
40. Prusiner S.B. (1986) Prions are novel infectious pathogens causing scrapie and Creutzfeldt-Jakob disease. BioEssays 5, 281-286
41. Weissmann C. et al. (2011) Prions on the move. EMBO Reports 12, 1109-1117
42. Unterberger U., Voigtlander T. and Budka H. (2005) Pathogenesis of prion diseases. Acta Neuropathologica 109, 32-48
43. Stahl N. et al. (1987) Scrapie prion protein contains a phos-phatidylinositol glycolipid. Cell 51, 229-240
44. Donne D.G. et al. (1997) Structure of the recombinant full-length hamster prion protein PrP(29-231): the N terminus is highly flexible. Proceedings of the National Academy of Sciences of the United States of America 94, 13452-13457
45. Altmeppen H.C. et al. (2013) Roles of endoproteolytic alpha-cleavage and shedding of the prion protein in neurodegeneration. FEBS Journal 280, 4338-4347
46. Riek R. et al. (1997) NMR characterization of the full-length recombinant murine prion protein, mPrP(23-231). FEBS Letters 413, 282-288
47. Riek R. et al. (1998) Prion protein NMR structure and familial human spongiform encephalopathies. Proceedings of the National Academy of Sciences of the United States of America 95, 11667-11672
48. Bueler H. et al. (1992) Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein. Nature 356, 577-582
49. Manson J.C. et al. (1994) 129/Ola mice carrying a null mutation in PrP that abolishes mRNA production are developmentally normal. Molecular Neurobiology 8, 121-127
50. Richt J.A. et al. (2007) Production of cattle lacking prion protein. Nature Biotechnology 25, 132-138
51. Yu G. et al. (2006) Functional disruption of the prion protein gene in cloned goats. Journal of General Virology 87 (Pt 4), 1019-1027
52. Yu G. et al. (2009) Generation of goats lacking prion protein. Molecular Reproduction and Development 76, 3
53. Benestad S.L. et al. (2012) Healthy goats naturally devoid of prion protein. Veterinary Research 43, 87
54. Mallucci G.R. et al. (2002) Post-natal knockout of prion protein alters hippocampal CA1 properties, but does not result in neurodegeneration. EMBO Journal 21, 202-210
55. Tobler I. et al. (1996) Altered circadian activity rhythms and sleep in mice devoid of prion protein. Nature 380, 639-642
56. Westergard L., Christensen H.M. and Harris D.A. (2007) The cellular prion protein (PrP(C)): its physiological function and role in disease. Biochimica et Biophysica Acta 1772, 629-644
57. Wadsworth J.D., Asante E.A. and Collinge J. (2010) Review: contribution of transgenic models to understanding human prion disease. Neuropathology and Applied Neurobiology 36, 576-597
58. Nazor K.E., Seward T. and Telling G.C. (2007) Motor behavioral and neuropathological deficits in mice deficient for normal prion protein expression. Biochimica et Biophysica Acta 1772, 645-653
59. Collinge J. et al. (1994) Prion protein is necessary for normal synaptic function. Nature 370, 295-297
60. Manson J.C. et al. (1995) PrP gene dosage and long term potentiation. Neurodegeneration 4, 113-114
61. Striebel J.F., Race B. and Chesebro B. (2013) Prion protein and susceptibility to kainate-induced seizures: genetic pitfalls in the use of PrP knockout mice. Prion 7, 280-285
62. Steele A.D., Lindquist S. and Aguzzi A. (2007) The prion protein knockout mouse: a phenotype under challenge. Prion 1, 83-93
63. Bueler H. et al. (1993) Mice devoid of PrP are resistant to scrapie. Cell 73, 1339-1347
64. Sailer A. et al. (1994) No propagation of prions in mice devoid of PrP. Cell 77, 967-968
65. Manson J.C. et al. (1994) PrP gene dosage determines the timing but not the final intensity or distribution of lesions in scrapie pathology. Neurodegeneration 3, 331-340
66. Kretzschmar H.A. et al. (1986) Scrapie prion proteins are synthesized in neurons. The American Journal of Pathology 122, 1-5
67. Moser M. et al. (1995) Developmental expression of the prion protein gene in glial cells. Neuron 14, 509-517
68. Brown H.R. et al. (1990) The mRNA encoding the scrapie agent protein is present in a variety of non-neuronal cells. Acta Neuropathologica 80, 1-6
69. Tanji K. et al. (1995) Analysis of PrPc mRNA by in situ hybridization in brain, placenta, uterus and testis of rats. Intervirology 38, 309-315
70. McLennan N.F. et al. (2001) In situ hybridization analysis of PrP mRNA in human CNS tissues. Neuropathology and Applied Neurobiology 27, 373-383
71. Bendheim P.E. et al. (1992) Nearly ubiquitous tissue distribution of the scrapie agent precursor protein. Neurology 42, 149-156
72. Ford M.J. et al. (2002) A marked disparity between the expression of prion protein and its message by neurones of the CNS. Neuroscience 111, 533-551
73. Laine J. et al. (2001) Cellular and subcellular morphological localization of normal prion protein in rodent cerebellum. European Journal of Neuroscience 14, 47-56
74. Gorodinsky A. and Harris D.A. (1995) Glycolipid-anchored proteins in neuroblastoma cells form detergent-resistant complexes without caveolin. Journal of Cell Biology 129, 19
75. Naslavsky N. et al. (1997) Characterization of detergent-insoluble complexes containing the cellular prion protein and its scrapie isoform. Journal of Biological Chemistry 272, 6324-6331
76. Jacobson K. and Dietrich C. (1999) Looking at lipid rafts? Trends in Cell Biology 9, 87-91
77. Mouillet-Richard S. et al. (2000) Signal transduction through prion protein. Science 289, 1925-1928
78. Chen S. et al. (2003) Prion protein as trans-interacting partner for neurons is involved in neurite outgrowth and neuronal survival. Molecular and Cellular Neurosciences 22, 227-233
79. Graner E. et al. (2000) Cellular prion protein binds laminin and mediates neuritogenesis. Molecular Brain Research 76, 85-92
80. Mironov A. Jr et al. (2003) Cytosolic prion protein in neurons. Journal of Neuroscience 23, 7183-7193
81. Fournier J.G. et al. (1995) Ultrastructural localization of cellular prion protein (PrPc) in synaptic boutons of normal hamster hippocampus. Comptes Rendus de l’Académie des Sciences – Series III 318, 339-344
82. Herms J. et al. (1999) Evidence of presynaptic location and function of the prion protein. Journal of Neuroscience 19, 8866-8875
83. Haeberle A.M. et al. (2000) Synaptic prion protein immuno-reactivity in the rodent cerebellum. Microscopy Research and Technique 50, 66-75
84. Moya K.L. et al. (2000) Immunolocalization of the cellular prion protein in normal brain. Microscopy Research and Technique 50, 58-65
85. Spielhaupter C. and Schatzl H.M. (2001) PrPC directly interacts with proteins involved in signaling pathways. Journal of Biological Chemistry 276, 44604-44612
86. Magalhaes A.C. et al. (2002) Endocytic intermediates involved with the intracellular trafficking of a fluorescent cellular prion protein. Journal of Biological Chemistry 277, 33311-33318
87. Senatore A. et al. (2012) Mutant PrP suppresses glutamatergic neurotransmission in cerebellar granule neurons by impairing membrane delivery of VGCC alpha(2)delta-1 Subunit. Neuron 74, 300-313
88. Robinson S.W. et al. (2014) Prion protein facilitates synaptic vesicle release by enhancing release probability. Human Molecular Genetics 23, 4581-4596
89. Ma J., Wollmann R. and Lindquist S. (2002) Neurotoxicity and neurodegeneration when PrP accumulates in the cytosol. Science 298, 1781-1785
90. Hofmann J. and Vorberg I. (2013) Life cycle of cytosolic prions. Prion 7, 369-377
91. Atoji Y. and Ishiguro N. (2009) Distribution of the cellular prion protein in the central nervous system of the chicken. Journal of Chemical Neuroanatomy 38, 292-301
92. Malaga-Trillo E. and Sempou E. (2009) PrPs: Proteins with a purpose: Lessons from the zebrafish. Prion 3, 129-133
93. Rivera-Milla E., Stuermer C.A. and Malaga-Trillo E. (2003) An evolutionary basis for scrapie disease: identification of a fish prion mRNA. Trends in Genetics 19, 72-75
94. Rivera-Milla E. et al. (2006) Disparate evolution of prion protein domains and the distinct origin of Doppel- and prion-related loci revealed by fish-to-mammal comparisons. FASEB Journal 20, 317-319
95. Miesbauer M. et al. (2006) Prion protein-related proteins from zebrafish are complex glycosylated and contain a glycosylpho-sphatidylinositol anchor. Biochemical and Biophysical Research Communications 341, 218-224
96. Malaga-Trillo E. et al. (2009) Regulation of embryonic cell adhesion by the prion protein. PLoS Biology 7, e55
97. Roucou X., Gains M. and LeBlanc A.C. (2004) Neuroprotective functions of prion protein. Journal of Neuroscience Research 75, 153-161
98. Pauly P.C. and Harris D.A. (1998) Copper stimulates endo-cytosis of the prion protein. Journal of Biological Chemistry 273, 33107-33110
99. Mange A. et al. (2002) PrP-dependent cell adhesion in N2a neuroblastoma cells. FEBS Letters 514, 159-162
100. Bremer J. et al. (2010) Axonal prion protein is required for peripheral myelin maintenance. Nature Neuroscience 13, 310-318
101. Nishida N. et al. (1999) A mouse prion protein transgene rescues mice deficient for the prion protein gene from Purkinje cell degeneration and demyelination. Laboratory Investigation 79, 689-697
102. Oh J.M. et al. (2008) The involvement of cellular prion protein in the autophagy pathway in neuronal cells. Molecular and Cellular Neurosciences 39, 238-247
103. Schmitt-Ulms G. et al. (2009) Evolutionary descent of prion genes from the ZIP family of metal ion transporters. PLoS ONE 4, e7208
104. Brown D.R. et al. (1999) Normal prion protein has an activity like that of superoxide dismutase. Biochemical Journal 344 (Pt 1), 1-5
105. Brown D.R. et al. (1997) The cellular prion protein binds copper in vivo. Nature 390, 684-687
106. Jones S. et al. (2005) Recombinant prion protein does not possess SOD-1 activity. Biochemical Journal 392 (Pt 2), 309-312
107. Hutter G., Heppner F.L. and Aguzzi A. (2003) No superoxide dismutase activity of cellular prion protein in vivo. Biological Chemistry 384, 1279-1285
108. Davies P. et al. (2011) Contribution of individual histidines to prion protein copper binding. Biochemistry 50, 10781-10791
109. Sakudo A. et al. (2005) PrP cooperates with STI1 to regulate SOD activity in PrP-deficient neuronal cell line. Biochemical and Biophysical Research Communications 328, 14-19
110. Kurschner C. and Morgan J.I. (1996) Analysis of interaction sites in homo- and heteromeric complexes containing Bcl-2 family members and the cellular prion protein. Molecular Brain Research 37, 249-258
111. Kurschner C. and Morgan J.I. (1995) The cellular prion protein (PrP) selectively binds to Bcl-2 in the yeast two-hybrid system. Molecular Brain Research 30, 165-168
112. Kuwahara C. et al. (1999) Prions prevent neuronal cell-line death. Nature 400, 225-226
113. Bounhar Y. et al. (2001) Prion protein protects human neurons against Bax-mediated apoptosis. Journal of Biological Chemistry 276, 39145-39149
114. Li A. and Harris D.A. (2005) Mammalian prion protein suppresses Bax-induced cell death in yeast. Journal of Biological Chemistry 280, 17430-17434
115. Chiesa R. et al. (2005) Bax deletion prevents neuronal loss but not neurological symptoms in a transgenic model of inherited prion disease. Proceedings of the National Academy of Sciences of the United States of America 102, 238-243
116. Zhang C.C. et al. (2006) Prion protein is expressed on long-term repopulating hematopoietic stem cells and is important for their self-renewal. Proceedings of the National Academy of Sciences of the United States of America 103, 2184-2189
117. Zomosa-Signoret V. et al. (2008) Physiological role of the cellular prion protein. Veterinary Research 39, 9
118. Ingram R.J. et al. (2009) A role of cellular prion protein in programming T-cell cytokine responses in disease. FASEB Journal 23, 1672-1684
119. Kubosaki A. et al. (2003) Expression of normal cellular prion protein (PrP(c)) on T lymphocytes and the effect of copper ion: Analysis by wild-type and prion protein gene-deficient mice. Biochemical and Biophysical Research Communications 307, 810-813
120. Ballerini C. et al. (2006) Functional implication of cellular prion protein in antigen-driven interactions between T cells and dendritic cells. Journal of Immunology 176, 7254-7262
121. Gunther E.C. and Strittmatter S.M. (2010) Beta-amyloid oligomers and cellular prion protein in Alzheimer’s disease. Journal of Molecular Medicine (Berl) 88, 331-338
122. Parkin E.T. et al. (2007) Cellular prion protein regulates beta-secretase cleavage of the Alzheimer’s amyloid precursor protein. Proceedings of the National Academy of Sciences of the United States of America 104, 11062-11067
123. Lauren J. et al. (2009) Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 457, 1128-1132
124. Barry A.E. et al. (2011) Alzheimer’s disease brain-derived amyloid-beta-mediated inhibition of LTP in vivo is prevented by immunotargeting cellular prion protein. The Journal of Neuroscience 31, 7259-7263
125. Freir D.B. et al. (2011) Interaction between prion protein and toxic amyloid [beta] assemblies can be therapeutically targeted at multiple sites. Nature Communications 2, 336
126. Gimbel D.A. et al. (2010) Memory impairment in transgenic Alzheimer mice requires cellular prion protein. Journal of Neuroscience 30, 6367-6374
127. Kudo W. et al. (2012) Cellular prion protein is essential for oligomeric amyloid-beta-induced neuronal cell death. Human Molecular Genetics 21, 1138-1144
128. Bate C. and Williams A. (2011) Amyloid-beta-induced synapse damage is mediated via cross-linkage of cellular prion proteins. Journal of Biological Chemistry 286, 37955-37963
129. Kessels H.W. et al. (2010) The prion protein as a receptor for amyloid-[beta]. Nature 466, E3-E4
130. Calella A.M. et al. (2010) Prion protein and Abeta-related synaptic toxicity impairment. EMBO Molecular Medicine 2, 306-314
131. Balducci C. et al. (2010) Synthetic amyloid-beta oligomers impair long-term memory independently of cellular prion protein. Proceedings of the National Academy of Sciences of the United States of America 107, 2295-2300
132. Cisse M. et al. (2011) Ablation of cellular prion protein does not ameliorate abnormal neural network activity or cognitive dysfunction in the J20 line of human amyloid precursor protein transgenic mice. Journal of Neuroscience 31, 10427-10431
133. Rial D. et al. (2012) Overexpression of cellular prion protein (PrP(C)) prevents cognitive dysfunction and apoptotic neuronal cell death induced by amyloid-beta (Abeta 1-40) administration in mice. Neuroscience 215, 79-89
134. Resenberger U.K. et al. (2011) The cellular prion protein mediates neurotoxic signalling of beta-sheet-rich conformers independent of prion replication. EMBO Journal 30, 2057-2070
135. You H. et al. (2012) Abeta neurotoxicity depends on interactions between copper ions, prion protein, and N-methyl-D-aspartate receptors. Proceedings of the National Academy of Sciences of the United States of America 109, 1737-1742
136. Um J.W. et al. (2012) Alzheimer amyloid-beta oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nature Neuroscience 15, 1227-1235
137. Kovacs G.G. and Budka H. (2008) Prion diseases: from protein to cell pathology. American Journal of Pathology 172, 555-565
138. Sikorska B. et al. (2009) Ultrastructural study of florid plaques in variant Creutzfeldt-Jakob disease: a comparison with amyloid plaques in kuru, sporadic Creutzfeldt-Jakob disease and Gerstmann–Straussler–Scheinker disease. Neuropathology and Applied Neurobiology 35, 46-59
139. Forloni G. et al. (1993) Neurotoxicity of a prion protein fragment. Nature 362, 543-546
140. Hetz C. et al. (2003) Caspase-12 and endoplasmic reticulum stress mediate neurotoxicity of pathological prion protein. EMBO Journal 22, 5435-5445
141. Budka H. (2000) Histopathology and immunohistochemistry of human transmissible spongiform encephalopathies (TSEs). Archives of Virology Supplementum 16, 135-142
142. Zou W.Q. and Gambetti P. (2007) Prion: the chameleon protein. Cellular and Molecular Life Sciences 64, 3266-3270
143. Yuan J. et al. (2006) Insoluble aggregates and protease-resistant conformers of prion protein in uninfected human brains. Journal of Biological Chemistry 281, 34848-34858
144. Hsiao K.K. et al. (1994) Serial transmission in rodents of neurodegeneration from transgenic mice expressing mutant prion protein. Proceedings of the National Academy of Sciences of the United States of America 91, 9126-9130
145. Tateishi J. et al. (1995) First experimental transmission of fatal familial insomnia. Nature 376, 434-435
146. Hayward P.A., Bell J.E. and Ironside J.W. (1994) Prion protein immunocytochemistry: reliable protocols for the investigation of Creutzfeldt-Jakob disease. Neuropathology and Applied Neurobiology 20, 375-383
147. Collinge J. et al. (1995) Transmission of fatal familial insomnia to laboratory animals. Lancet 346, 569-570
148. Sandberg M.K. et al. (2014) Prion neuropathology follows the accumulation of alternate prion protein isoforms after infective titre has peaked. Nature Communications 5, 4347
149. Chesebro B. et al. (2010) Fatal transmissible amyloid encephalopathy: a new type of prion disease associated with lack of prion protein membrane anchoring. PLoS Pathogens 6, e1000800
150. Bueler H. et al. (1994) High prion and PrPSc levels but delayed onset of disease in scrapie-inoculated mice heterozygous for a disrupted PrP gene. Molecular Medicine 1, 19-30
151. Sandberg M.K. et al. (2011) Prion propagation and toxicity in vivo occur in two distinct mechanistic phases. Nature 470, 540-542
152. Hill A.F. and Collinge J. (2003) Subclinical prion infection. Trends in Microbiology 11, 578-584
153. Race R. et al. (2001) Long-term subclinical carrier state precedes scrapie replication and adaptation in a resistant species: analogies to bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease in humans. Journal of Virology 75, 10106-10112
154. Thackray A.M. et al. (2002) Chronic subclinical prion disease induced by low-dose inoculum. Journal of Virology 76, 2510-2517
155. Thackray A.M., Klein M.A. and Bujdoso R. (2003) Subclinical prion disease induced by oral inoculation. Journal of Virology 77, 7991-7998
156. Asante E.A. et al. (2002) BSE prions propagate as either variant CJD-like or sporadic CJD-like prion strains in transgenic mice expressing human prion protein. EMBO Journal 21, 6358-6366
157. Hill A.F. et al. (2000) Species-barrier-independent prion replication in apparently resistant species. Proceedings of the National Academy of Sciences of the United States of America 97, 10248-10253
158. Brandner S. et al. (1996) Normal host prion protein necessary for scrapie-induced neurotoxicity. Nature 379, 339-343
159. Aguzzi A. et al. (1998) Use of brain grafts to study the pathogenesis of prion diseases. Essays in Biochemistry 33, 133-147
160. Mallucci G. et al. (2003) Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. Science 302, 871-874
161. Kazlauskaite J. et al. (2005) An unusual soluble beta-turn-rich conformation of prion is involved in fibril formation and toxic to neuronal cells. Biochemical and Biophysical Research Communications 328, 292-305
162. Masel J., Genoud N. and Aguzzi A. (2005) Efficient inhibition of prion replication by PrP-Fc(2) suggests that the prion is a PrP(Sc) oligomer. Journal of Molecular Biology 345, 1243-1251
163. Haass C. and Selkoe D.J. (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer’s amyloid beta-peptide. Nature Reviews. Molecular Cell Biology 8, 101-112
164. Weissmann C. et al. (2002) Molecular biology of prions. Acta Neurobiologiae Experimentalis 62, 153-166
165. Simoneau S. et al. (2007) In vitro and in vivo neurotoxicity of prion protein oligomers. PLoS Pathogens 3, e125
166. Novitskaya V. et al. (2006) Amyloid fibrils of mammalian prion protein are highly toxic to cultured cells and primary neurons. Journal of Biological Chemistry 281, 13828-13836
167. Brandner S. et al. (1996) Normal host prion protein (PrPC) is required for scrapie spread within the central nervous system. Proceedings of the National Academy of Sciences of the United States of America 93, 13148-13151
168. Harris D.A. and True H.L. (2006) New insights into prion structure and toxicity. Neuron 50, 353-357
169. Chesebro B. et al. (2005) Anchorless prion protein results in infectious amyloid disease without clinical scrapie. Science 308, 1435-1439
170. Zhou M. et al. (2012) Highly neurotoxic monomeric alpha-helical prion protein. Proceedings of the National Academy of Sciences of the United States of America 109, 3113-3118
171. Halliday M., Radford H. and Mallucci G.R. (2014) Prions: generation and spread versus neurotoxicity. Journal of Biological Chemistry 289, 19862-19868
172. Trifilo M.J. et al. (2006) Prion-induced amyloid heart disease with high blood infectivity in transgenic mice. Science 313, 94-97
173. Klingeborn M. et al. (2011) Crucial role for prion protein membrane anchoring in the neuroinvasion and neural spread of prion infection. Journal of Virology 85, 1484-1494
174. Ghetti B. et al. (1996) Vascular variant of prion protein cerebral amyloidosis with tau-positive neurofibrillary tangles: the phenotype of the stop codon 145 mutation in PRNP. Proceedings of the National Academy of Sciences of the United States of America 93, 744-748
175. Revesz T. et al. (2009) Genetics and molecular pathogenesis of sporadic and hereditary cerebral amyloid angiopathies. Acta Neuropathologica 118, 115-130
176. Jansen C. et al. (2010) Prion protein amyloidosis with divergent phenotype associated with two novel nonsense mutations in PRNP. Acta Neuropathologica 119, 189-197
177. Gambetti P. et al. (2003) Sporadic and familial CJD: classification and characterisation. British Medical Bulletin 66, 213-239
178. Moore R.A. et al. (2014) Proteomics analysis of amyloid and nonamyloid prion disease phenotypes reveals both common and divergent mechanisms of neuropathogenesis. Journal of Proteome Research 13, 4620-4634
179. Budka H. (2003) Neuropathology of prion diseases. British Medical Bulletin 66, 121-130
180. Klionsky D.J. (2000) Autophagy as a regulated pathway of cellular degradation. Science 290, 1717-1721
181. Heiseke A., Aguib Y. and Schatzl H.M. (2010) Autophagy, prion infection and their mutual interactions. Current Issues in Molecular Biology 12, 11
182. Rubinsztein D.C. et al. (2005) Autophagy and its possible roles in nervous system diseases, damage and repair. Autophagy 1, 11-22
183. Boellaard J.W., Schlote W. and Tateishi J. (1989) Neuronal autophagy in experimental Creutzfeldt-Jakob’s disease. Acta Neuropathologica 78, 410-418
184. Liberski P.P., Gajdusek D. and Brown P. (2002) How do neurons degenerate in prion diseases or transmissible spongiform encephalopathies (TSEs): neuronal autophagy revisited. Acta Neurobiologiae Experimentalis 62, 7
185. Liberski P.P. et al. (2004) Neuronal cell death in transmissible spongiform encephalopathies (prion diseases) revisited: from apoptosis to autophagy. International Journal of Biochemistry & Cell Biology 36, 2473-2490
186. Beranger F. et al. (2008) Trehalose impairs aggregation of PrPSc molecules and protects prion-infected cells against oxidative damage. Biochemical and Biophysical Research Communications 374, 44-48
187. Aguib Y. et al. (2009) Autophagy induction by trehalose counter-acts cellular prion-infection. Autophagy 5, 9
188. Heiseke A. et al. (2009) Lithium induces clearance of protease resistant prion protein in prion-infected cells by induction of autophagy. Journal of Neurochemistry 109, 25-34
189. Ertmer A. et al. (2004) The tyrosine kinase inhibitor STI571 induces cellular clearance of PrPSc in prion-infected cells. Journal of Biological Chemistry 279, 41918-41927
190. Yun S.W. et al. (2007) The tyrosine kinase inhibitor imatinib mesylate delays prion neuroinvasion by inhibiting prion propagation in the periphery. Journal of Neurovirology 13, 328-337
191. + replenishment. Brain 138 (Pt 4), 992-1008
192. Cortes C.J. et al. (2012) Rapamycin delays disease onset and prevents PrP plaque deposition in a mouse model of Gerstmann–Straussler–Scheinker disease. Journal of Neuroscience 32, 12396-12405
193. Giese A. et al. (1995) Neuronal cell death in scrapie-infected mice is due to apoptosis. Brain Pathology 5, 213-221
194. Lucassen P.J. et al. (1995) Detection of apoptosis in murine scrapie. Neuroscience Letters 198, 185-188
195. Jesionek-Kupnicka D. et al. (1997) Programmed cell death (apoptosis) in Alzheimer’s disease and Creutzfeldt–Jakob disease. Folia Neuropathologica 35, 233-235
196. Pillot T. et al. (2000) A nonfibrillar form of the fusogenic prion protein fragment [118–135] induces apoptotic cell death in rat cortical neurons. Journal of Neurochemistry 75, 2298-2308
197. O’Donovan C.N., Tobin D. and Cotter T.G. (2001) Prion protein fragment PrP-(106-126) induces apoptosis via mitochondrial disruption in human neuronal SH-SY5Y cells. Journal of Biological Chemistry 276, 43516-43523
198. Lin D.T. et al. (2008) Cytosolic prion protein is the predominant anti-Bax prion protein form: exclusion of transmembrane and secreted prion protein forms in the anti-Bax function. Biochimica et Biophysica Acta 1783, 2001-2012
199. Chiesa R. et al. (2000) Accumulation of protease-resistant prion protein (PrP) and apoptosis of cerebellar granule cells in transgenic mice expressing a PrP insertional mutation. Proceedings of the National Academy of Sciences of the United States of America 97, 5574-5579
200. Coulpier M. et al. (2006) Bax deletion does not protect neurons from BSE-induced death. Neurobiology of Disease 23, 603-611
201. Siso S. et al. (2002) Abnormal synaptic protein expression and cell death in murine scrapie. Acta Neuropathologica 103, 615-626
202. Nakagawa T. et al. (2000) Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta. Nature 403, 98-103
203. Mansuy I.M. (2003) Calcineurin in memory and bidirectional plasticity. Biochemical and Biophysical Research Communications 311, 1195-1208
204. Steele A.D. et al. (2007) Prion pathogenesis is independent of caspase-12. Prion 1, 243-247
205. Soto C. and Satani N. (2011) The intricate mechanisms of neurodegeneration in prion diseases. Trends in Molecular Medicine 17, 14-24
206. Torres M. et al. (2010) Prion protein misfolding affects calcium homeostasis and sensitizes cells to endoplasmic reticulum stress. PLoS ONE 5, e15658
207. Mukherjee A. et al. (2010) Calcineurin inhibition at the clinical phase of prion disease reduces neurodegeneration, improves behavioral alterations and increases animal survival. PLoS Pathogens 6, e1001138
208. Shmerling D. et al. (1998) Expression of amino-terminally truncated PrP in the mouse leading to ataxia and specific cerebellar lesions. Cell 93, 203-214
209. Li A. et al. (2007) Neonatal lethality in transgenic mice expressing prion protein with a deletion of residues 105-125. EMBO Journal 26, 548-558
210. Baumann F. et al. (2007) Lethal recessive myelin toxicity of prion protein lacking its central domain. EMBO Journal 26, 538-547
211. Solomon I.H., Schepker J.A. and Harris D.A. (2010) Prion neurotoxicity: insights from prion protein mutants. Current Issues in Molecular Biology 12, 51-61
212. Christensen H.M. et al. (2010) A highly toxic cellular prion protein induces a novel, nonapoptotic form of neuronal death. American Journal of Pathology 176, 2695-2706
213. Orsi A. et al. (2006) Conditions of endoplasmic reticulum stress favor the accumulation of cytosolic prion protein. Journal of Biological Chemistry 281, 30431-30438
214. Rane N.S. et al. (2008) Reduced translocation of nascent prion protein during ER stress contributes to neurodegeneration. Developmental Cell 15, 359-370
215. Kang S.W. et al. (2006) Substrate-specific translocational attenuation during ER stress defines a pre-emptive quality control pathway. Cell 127, 999-1013
216. Drisaldi B. et al. (2003) Mutant PrP is delayed in its exit from the endoplasmic reticulum, but neither wild-type nor mutant PrP undergoes retrotranslocation prior to proteasomal degradation. Journal of Biological Chemistry 278, 21732-21743
217. Walter P. and Ron D. (2011) The unfolded protein response: from stress pathway to homeostatic regulation. Science 334, 1081-1086
218. Lindholm D., Wootz H. and Korhonen L. (2006) ER stress and neurodegenerative diseases. Cell Death and Differentiation 13, 385-392
219. Hetz C. et al. (2008) Unfolded protein response transcription factor XBP-1 does not influence prion replication or pathogenesis. Proceedings of the National Academy of Sciences of the United States of America 105, 757-762
220. Teske B.F. et al. (2011) The eIF2 kinase PERK and the integrated stress response facilitate activation of ATF6 during endoplasmic reticulum stress. Molecular Biology of the Cell 22, 4390-4405
221. Hetz C., Castilla J. and Soto C. (2007) Perturbation of endoplasmic reticulum homeostasis facilitates prion replication. Journal of Biological Chemistry 282, 12725-12733
222. Moreno J.A. et al. (2012) Sustained translational repression by eIF2alpha-P mediates prion neurodegeneration. Nature 485, 507-511
223. Ciechanover A. and Brundin P. (2003) The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg. Neuron 40, 427-446
224. Ma J. and Lindquist S. (2002) Conversion of PrP to a self-perpetuating PrPSc-like conformation in the cytosol. Science 298, 1785-1788
225. Yedidia Y. et al. (2001) Proteasomes and ubiquitin are involved in the turnover of the wild-type prion protein. EMBO Journal 20, 5383-5391
226. Lowe J. et al. (1992) Immunoreactivity to ubiquitin-protein conjugates is present early in the disease process in the brains of scrapie-infected mice. Journal of Pathology 168, 169-177
227. Ironside J.W. et al. (1993) Ubiquitin immunocytochemistry in human spongiform encephalopathies. Neuropathology and Applied Neurobiology 19, 134-140
228. Kovacs G.G. et al. (2005) Subcellular localization of disease-associated prion protein in the human brain. American Journal of Pathology 166, 287-294
229. Kang S.C. et al. (2004) Prion protein is ubiquitinated after developing protease resistance in the brains of scrapie-infected mice. Journal of Pathology 203, 603-608
230. Kristiansen M. et al. (2005) Disease-related prion protein forms aggresomes in neuronal cells leading to caspase activation and apoptosis. Journal of Biological Chemistry 280, 38851-38861
231. Kristiansen M. et al. (2007) Disease-associated prion protein oligomers inhibit the 26S proteasome. Molecular Cell 26, 175-188
232. Jamieson E. et al. (2001) Activation of Fas and caspase 3 precedes PrP accumulation in 87 V scrapie. Neuroreport 12, 3567-3572
233. Quaglio E. et al. (2011) Expression of mutant or cytosolic PrP in transgenic mice and cells is not associated with endoplasmic reticulum stress or proteasome dysfunction. PLoS ONE 6, e19339
234. Lloyd S.E. et al. (2009) HECTD2 is associated with susceptibility to mouse and human prion disease. PLoS Genetics 5, e1000383
235. Jeffrey M. et al. (2009) Prion protein with an insertional mutation accumulates on axonal and dendritic plasmalemma and is associated with distinctive ultrastructural changes. American Journal of Pathology 175, 1208-1217
236. Chiesa R. et al. (2003) Molecular distinction between pathogenic and infectious properties of the prion protein. Journal of Virology 77, 7611-7622
237. Lasmezas C.I. et al. (1996) Strain specific and common pathogenic events in murine models of scrapie and bovine spongiform encephalopathy. Journal of General Virology 77 (Pt 7), 1601-1609
238. Trevitt C.R. and Collinge J. (2006) A systematic review of prion therapeutics in experimental models. Brain 129 (Pt 9), 2241-2265
239. Moreno J.A. et al. (2013) Oral treatment targeting the unfolded protein response prevents neurodegeneration and clinical disease in prion-infected mice. Science Translational Medicine 5, 206ra138
240. Halliday M. et al. (2015) Partial restoration of protein synthesis rates by the small molecule ISRIB prevents neurodegeneration without pancreatic toxicity. Cell Death & Disease 6, e1672
241. Wisniewski T. and Goni F. (2012) Could immunomodulation be used to prevent prion diseases? Expert Review of Anti-Infective Therapy 10, 307-317
242. Roettger Y. et al. (2013) Immunotherapy in prion disease. Nature Reviews Neurology 9, 98-105
243. Schenk D. et al. (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173-177
244. Enari M., Flechsig E. and Weissmann C. (2001) Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody. Proceedings of the National Academy of Sciences of the United States of America 98, 9295-9299
245. Peretz D. et al. (2001) Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature 412, 739-743
246. White A.R. et al. (2003) Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature 422, 80-83
247. Goni F. et al. (2005) Mucosal vaccination delays or prevents prion infection via an oral route. Neuroscience 133, 413-421
248. Goni F. et al. (2015) Mucosal immunization with an attenuated Salmonella vaccine partially protects white-tailed deer from chronic wasting disease. Vaccine 33, 726-733